MedPath

Acelyrin's Izokibep Advances in Phase 3 Trials Amidst Analyst Revisions and Institutional Investment

• Acelyrin's lead drug candidate, Izokibep, is currently in Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and Phase 2 trials for Axial Spondyloarthritis. • Institutional investors, including Point72 Asset Management L.P., have increased their positions in Acelyrin, indicating confidence in the company's potential. • Several analysts have adjusted their price targets for Acelyrin, reflecting evolving expectations for the company's performance and the potential of Izokibep. • Acelyrin's stock experienced trading fluctuations, highlighting the dynamic nature of the biopharmaceutical market and investor sentiment towards the company.

Acelyrin, Inc. (NASDAQ:SLRN) is progressing with Phase 3 clinical trials for its primary drug candidate, izokibep, aimed at treating Hidradenitis Suppurativa (HS), Psoriatic Arthritis (PsA), and uveitis. Additionally, izokibep is in Phase 2 clinical trials for Axial Spondyloarthritis (axSpA). These trials are designed to evaluate the efficacy and safety of izokibep, a small protein therapeutic engineered to inhibit IL-17A with high potency.
Point72 Asset Management L.P. significantly increased its stake in Acelyrin during the third quarter, raising its holdings by 566.7% to 250,300 shares, valued at $1.23 million. Other institutional investors, including Millennium Management LLC, Blue Owl Capital Holdings LP, Charles Schwab Investment Management Inc., Renaissance Technologies LLC, and Almitas Capital LLC, have also adjusted their positions in Acelyrin, reflecting ongoing interest and investment in the company.

Analyst Outlook

Recent analyst reports indicate varied perspectives on Acelyrin's stock. HC Wainwright reiterated a "neutral" rating with an $8.00 price target. Wells Fargo & Company reduced their price objective from $15.00 to $13.00, maintaining an "overweight" rating. Piper Sandler decreased their target price from $68.00 to $20.00, also with an "overweight" rating. Morgan Stanley cut their price target from $13.00 to $6.00, assigning an "equal weight" rating. These adjustments reflect evolving expectations for Acelyrin's performance and the potential of izokibep.

Stock Performance

Acelyrin's stock experienced a decline of $0.47, trading at $3.59 on Wednesday, with a trading volume of 2,051,460 shares. The company has a market capitalization of $360.18 million, a PE ratio of -1.35, and a beta of 1.63. The stock's 50-day simple moving average is $5.29, and its 200-day simple moving average is $5.02. Acelyrin's 12-month low is $3.18, and its 12-month high is $8.89.

Izokibep Clinical Trials

Izokibep is currently undergoing Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and Phase 2 clinical trials for Axial Spondyloarthritis. These trials aim to assess the drug's ability to inhibit IL-17A, a key cytokine involved in inflammatory diseases. The outcomes of these trials will be crucial in determining the future of izokibep as a potential treatment option for these conditions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Acelyrin's Lonigutamab Shows Promise in Thyroid Eye Disease with Optimized Dosing Strategy

Acelyrin's lonigutamab Phase 1/2 study update reveals that lower doses administered every four weeks were subtherapeutic for thyroid eye disease (TED).
The company's analysis determined that a minimum concentration of 3 ug/ml is required for maximized efficacy, achievable with a 100 mg loading dose followed by 50 mg every two weeks.

Acelyrin's Lonigutamab Shows Promise in Thyroid Eye Disease Phase 2 Data

Acelyrin will present Phase 2 data for subcutaneous Lonigutamab, indicating a potentially best-in-class efficacy and safety profile for Thyroid Eye Disease (TED).
The company plans to unveil the design for its Phase 3 program following a successful meeting with the FDA.

Acelyrin Inc. Faces Market Volatility Amidst Clinical Trial Updates

Acelyrin Inc. (SLRN) stock reached a 52-week low amidst challenging market conditions, reflecting broader economic pressures and investor concerns.
The Phase 2b/3 study of izokibep for uveitis treatment failed to meet its primary endpoint, showing no statistically significant difference from placebo.

Acelyrin Prioritizes Lonigutamab for Thyroid Eye Disease After Positive Phase 1/2 Data

Acelyrin focuses on lonigutamab for Thyroid Eye Disease (TED) after promising Phase 1/2 results, with Phase 3 trials expected to begin in Q1 2025.
Lonigutamab shows advantages over anti-IGF-1R therapies, including no hyperglycemia, lower Cmax for reduced hearing loss risk, and higher potency at lower doses.

Acelyrin Re-prioritizes Pipeline After Mixed Izokibep Results, Shifts Focus to Lonigutamab

Acelyrin's Phase 3 trial of izokibep for hidradenitis suppurativa (HS) met its primary endpoint, with 33% of patients achieving HiSCR75 at Week 12 compared to 21% on placebo.
Despite positive results, Acelyrin will not advance izokibep for HS or psoriatic arthritis (PsA) due to competitive concerns and insufficient efficacy.

Acelyrin's Izokibep Shows Positive Phase 3 Data in Hidradenitis Suppurativa; Company Prioritizes Lonigutamab

Acelyrin's Phase 3 trial of izokibep in hidradenitis suppurativa (HS) met the primary endpoint, demonstrating a statistically significant Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at 12 weeks.
The company is shifting its focus to lonigutamab for thyroid eye disease (TED), with plans to initiate Phase 3 trials in Q1 2025 and extend its cash runway to mid-2027.

Acelyrin Provides Update on Clinical Programs and Business Strategy

Acelyrin completed enrollment in the Phase 3 trial of izokibep for hidradenitis suppurativa, with top-line data expected in the third quarter of 2024.
Positive proof-of-concept data were reported for lonigutamab in thyroid eye disease, with a Phase 2b/3 trial planned for initiation in the second half of 2024.

Acelyrin's Clinical Programs Advance with Robust Financial Backing

Acelyrin reported a strong cash position of $788.4 million, expected to fund operations through key clinical milestones in its autoimmune and inflammatory disease programs.
The company's Phase 2b/3 trial for izokibep in Psoriatic Arthritis (PsA) and the proof-of-concept study for lonigutamab in thyroid eye disease are progressing, with key data expected in Q1 2024.

Acelyrin's Izokibep Fails to Meet Primary Endpoint in Phase 2b/3 Psoriasis Trial, Stock Plummets

Acelyrin's stock price plummeted after its investigational drug, izokibep, failed to achieve the primary endpoint in a Phase 2b/3 clinical trial for moderate-to-severe psoriasis.
The trial results were described as "painfully disappointing" by analysts, leading to a significant reduction in the company's price target by Jefferies.

ACELYRIN's Izokibep Shows Promise in Hidradenitis Suppurativa and Psoriatic Arthritis Trials

Early data from a Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa (HS) shows improvement in draining tunnels in two-thirds of patients by week 4.
Enrollment is complete for the Phase 2b/3 trial of izokibep in Psoriatic Arthritis (PsA), with top-line data expected in Q1 2024, accelerated from mid-2024.

Reference News

[1]
Point72 Asset Management L.P. Has $1.23 Million Position in Acelyrin, Inc. (NASDAQ:SLRN)
marketbeat.com · Dec 11, 2024

Point72 Asset Management increased its stake in Acelyrin by 566.7% in Q3, owning 250,300 shares. Other hedge funds also ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy